Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Clinical trial NCT05519410 · UNKNOWN
Trial details
- NCT number
- NCT05519410
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-23
- Primary completion
- 2024-09-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.